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Abstract: The purpose of this work is to explore the potential contribution of diffusion MRI to predict the effects of 
irreversible electroporation (IRE) in a pancreatic ductal adenocarcinoma (PDAC) mouse model. Thirteen mice were 
injected with Panc-02 PDAC cells in both flanks. One tumor was treated with IRE when it reached a diameter of about 
5 mm. T2- and diffusion-weighted MRI sequences were acquired before IRE treatment and 1, 3 and 7 days later. The 
mice were euthanized 1 day (n = 6) or 2 weeks (n = 7) after treatment. The tumors were excised and stained with 
H&E, caspase-3, CD-3, F4/80. The volume and the mean and standard deviation of the apparent diffusion coeffi-
cient (ADC) were compared between treated and untreated lesions and correlated with histology-derived measures. 
At 1-day post-treatment, a dramatic ADC increase (+50.81%, P < 0.05) was found in ablated lesions, strongly corre-
lated with apoptosis (τ = 0.90). At later time points the ADC returned to pre-treatment values, though histopathology 
showed a quite different scenario compared to the untreated controls. The ADC standard deviation measured within 
the treated tumors 1 day after IRE treatment had a strong negative correlation with the number of tumor cells found 
14 days later (τ = 0.80). There was also a strong correlation between 1-day ADC and 14-day apoptosis in untreated 
tumors (τ = 0.95). In conclusion, diffusion MRI is sensitive to the short-term effects of IRE in PDAC tumors, and can 
help predict the long-term treatment outcome.
Keywords: Irreversible electroporation, diffusion MRI, apparent diffusion coefficient, pancreatic cancer, treatment 
outcome, apoptosis, early prediction, mouse model
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is 
one of the most aggressive cancers and is the 
fourth most frequent tumor-related cause of 
death in the Western world. It is difficult to keep 
long-term control on locally advanced disease 
[1]. About a third of patients with PDAC present 
with locally advanced disease that is not 
amenable to resection [2]. Systemic chemo- 
therapies and molecularly targeted therapies 
have offered no or little survival benefit [3]. 
When surgical options are precluded, image-
guided tumor ablation is recommended as the 
most appropriate therapeutic choice. Con- 
ventional ablative therapies (chemical ablation, 
thermal ablation, and cryoablation) have the 
potential to be beneficial for locally advanced 
PDAC [4]. IRE consists in the application of 
short high-intensity pulses of electric field that 
create nanopores in the cell membrane and 
ultimately lead to apoptosis in the target tissue 
[5]; this mechanism has been known for de- 
cades but its application in cancer treatment is 
relatively recent [6, 7]. IRE represents a new 
non-thermal injury ablative technique, which 
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allows definitively treating a soft tissue tumor 
with a decreased risk of thermal damage to 
vital structures adjacent to pancreatic tissue 
[8]. The clinical applications of IRE are growing, 
especially for liver and pancreatic cancer treat-
ment [9-12]. 
Non-invasive imaging plays a fundamental role 
in planning IRE procedures, guiding electrode 
placement, assessing the treatment effects 
and detecting complications. Although ultra-
sound and computed tomography are the most 
widely used techniques in this context, particu-
larly before and during the intervention, mag-
netic resonance imaging (MRI) has shown its 
potential superiority in some studies [13] and is 
increasingly being utilized for both screening 
and therapy assessment. However, only T2- 
weighted and contrast-enhanced T1-weighted 
sequences are commonly used; the utility of 
advanced MRI techniques has not been thor-
oughly investigated [14].
Diffusion MRI (dMRI) is sensitive to water dis-
placement in tissue and thus indirectly to tis-
sue microstructure [15, 16]; dMRI has become 
popular in research studies and clinical prac-
tice, mainly for its sensitivity to many pathologi-
cal alterations and relative ease of implemen-
tation. It may be an ideal candidate for 
characterizing tumors before and after treat-
ment, but it has been applied in IRE studies 
only sporadically and with quite diverse proto-
cols and results [13, 17-20]. In particular, one 
group focused on the change in apparent diffu-
sion coefficient (ADC) shortly after electropora-
tion, but with lower voltage than commonly 
used and with no validation by histology or 
other modalities to understand the basis of this 
alteration [21].
The purpose of our work is to investigate the 
possibility of characterizing IRE-treated tumors 
with dMRI and to assess what information it 
can provide. We studied the ADC time evolution 
in a pancreatic mouse tumor model after IRE, 
and we correlated ADC values with histopathol-
ogy data at both early and late time points after 
treatment.
Materials and methods
Pancreatic tumor animal model and study 
timeline
The mouse Panc-02 cell line is derived from 
amethylcholanthrene-induced PDAC in C57BL/ 
6 mice and was purchased from the American 
Type Culture Collection (ATCC; Rockville, MD). 
Panc-02 cells were maintained in RPMI 1640 
media (Life Technologies, Carlsbad, CA) supple-
mented with glutamine (2 mmol/l, Life Tech- 
nologies), pyruvate (1 mmol/l, Sigma-Aldrich, 
St. Louis, MO), penicillin and streptomycin (100 
IU/ml, Sigma-Aldrich), and 10% fetal bovine 
serum (FBS, Sigma-Aldrich). The cells were 
maintained in a humidified atmosphere of 5% 
CO2 at 37°C. Before implantation, cell viability 
was assessed using trypan blue (Sigma-Aldrich) 
staining (cell viability > 90% was confirmed 
prior to tumor implantation). Thirteen female 
C57BL/6 mice (4 weeks of age, weighing 
between 13 and 17 g) were used for our study. 
Early-passage Panc-02 cells were harvested 
and about 2 × 106 cells suspended in 200 µL of 
phosphate buffered saline (PBS) were subcuta-
neously implanted into the left and right flanks 
of each mouse. 
All the animals were visually checked every day 
and underwent checkup MRI at first signs of 
tumor growth. When the maximum linear size of 
either tumor reached about 5 mm, a baseline 
MRI was acquired, and IRE treatment was per-
formed the next day. All the mice underwent 
MRI again one day after treatment and 6 mice 
were sacrificed at this time point. The other 7 
mice were followed-up for two weeks, with addi-
tional MRI scans at 3 and 7 days. Two of these 
7 mice had to be terminated after the 7-day 
MRI for general adverse health conditions; the 
other 5 mice were sacrificed 14 days after IRE.
Irreversible electroporation
A square-wave Electroporator (ECM830, BTX/
Harvard apparatus, Holliston, MA, USA) with a 
parallel two-needle electrode array was used 
for all the IRE procedures. The electrode array 
consisted of two platinum-15% iridium needles 
inserted in a plastic block with a 5-mm spacing. 
The IRE ablation protocol, based on our previ-
ous studies [22-24], included five 2.5 kV 
square-wave pulses, with a length of 100 μs 
and an interval of 100 ms between them. The 
right-side tumor was treated, unless when it 
was smaller than 5 mm in diameter and the 
left-side tumor was larger. The mice were kept 
under anesthesia with 5% isoflurane in 2 L/
minute oxygen during the procedure.
MRI acquisition
MRI experiments were performed on a 7T pre-
clinical scanner (ClinScan, Bruker BioSpin, 
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Ettlingen, Germany). The checkup MRI protocol 
consisted of a coronal (TE = 39 ms, TR = 2750 
ms, voxel size = 0.13 × 0.13 × 0.7 mm3, FOV = 
30 × 30 mm2) and an axial (TE = 40 ms, TR = 
4550 ms, voxel size = 0.078 × 0.078 × 0.7 
mm3, FOV = 30 × 30 mm2) T2-weighted (T2W) 
sequence.
The baseline and post-treatment scans includ-
ed the T2W sequences mentioned above and a 
respiratory-triggered diffusion-weighted imag-
ing (DWI) sequence (TE = 40 ms, TR = 4800 
ms, voxel size = 0.3 × 0.3 × 1.5 mm3, FOV = 30 
× 30 mm2, b = 0, 200, 400, 650, 900, 1200 s/
mm2, 3 orthogonal gradient directions).
MRI processing
The volume of each lesion was measured by 
manual segmentation of the axial T2W images. 
A standard mono-exponential model was fitted 
to the dMRI signal using a custom code in 
Matlab (Mathworks, Natick, MA, USA):
E=exp(-b·ADC)
where b is the b-value (degree of diffusion 
weighting), E is the dMRI signal normalized to 
the b = 0 volume, and ADC is the Apparent 
Diffusion Coefficient, the only free parameter in 
this model.
Regions of Interest (ROIs) were delineated over 
the whole tumors on dMRI images and the 
mean and standard deviation of the ADC within 
each ROI were calculated. At post-treatment 
time points, the relative change of the mean 
ADC compared to baseline was also calculated 
as:
ADC ADC
ADC ADC
day_x
baseline
day_x baseline=
-
3
Histopathology
One day (first group) or 14 days (second group) 
after IRE, the mice were euthanized, and the 
tumors were excised. Each tumor sample was 
fixed in 10% formalin, embedded in paraffin, 
and sliced (5 µm slice thickness). Some slices 
were placed on glass slides for hematoxylin 
and eosin (H&E) staining. Other tumor slices 
were immunostained using antibodies against 
cleaved caspase-3 (Biocare Medical, Concord, 
CA) assays by utilizing kits according to the 
manufacturer’s instructions for analysis of 
apoptotic cell death [25, 26]. The other tumor 
slices were immunostained using antibodies 
against CD3 and F4/80 (Biocare Medical, 
Concord, CA) respectively. The total number of 
tumor cells (on H&E-stained slices), tumor 
apoptotic cells (caspase-3 positive cells), T 
Figure 1. Representative MR images. T2W images, DWI, and ADC maps of baseline, 1 day post-IRE, 3 days post-IRE, 
and 7 days post-IRE (IRE-treated tumor-red cycle, untreated tumor-blue cycle). These tumor masses were hyper-
intense (signal intensity is higher than normal muscle signal intensity) within T2W images and DWI images. IRE-
treated tumors were typically isointense within ADC maps while untreated tumors were hypointense. 
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cells (CD3 positive cells) and macrophage cells 
(F4/80 positive cells) were counted under 
microscopy in 5 views (× 20) for each control or 
IRE-treated tumor. All counts were performed 
by two investigators (Drs. ZZ and QM, with more 
than 10 years of experience) using a double-
headed light microscope.
Statistical analysis
The mean, standard deviation, and relative 
change of the ADC at each time point were 
compared between treated and untreated 
tumors using a Wilcoxon signed-rank test. 
Within each of the groups of lesions, the same 
parameters at each post-treatment timepoint 
were also compared to the corresponding base-
line values using a Wilcoxon signed-rank test. A 
p-value lower than 0.05 was considered signifi-
cant for all the comparisons. The correlation 
between the dMRI parameters at each time 
point and the number of tumor cells, apoptotic 
cells, T cells, macrophages or the MRI-derived 
relative volume change 7 days after IRE was 
evaluated with Kendall’s tau.
Results
MRI findings
T2W images, DWI (b = 650 s/mm2), and ADC 
maps of baseline, 1 day post-IRE, 3 days post-
IRE, and 7 days post-IRE (IRE treated tumor-red 
cycle, untreated tumor-blue cycle) are shown in 
Figure 1. These tumor masses were consistent-
ly hyperintense within T2W images and DWI 
images. IRE-treated tumors were typically isoin-
tense within ADC maps while untreated tumors 
were hypointense. 
Based on tumor volume measurement using 
T2w images, all the untreated tumors grew with 
time, from 40.47 ± 17.16 mm3 at baseline to 
82.22 ± 39.22 mm3 at 7 days. The treated 
tumors decreased on average, from 79.29 ± 
97.44 mm3 at baseline, to 70.60 ± 92.79 mm3 
at 7 days post-treatment (Figure 2A), but the 
variability was high and 3 out of 7 treated 
lesions increased in volume.
The mean and standard deviation of the ADC 
remained constant in the untreated tumors, 
with no statistically significant difference at any 
time point compared to the baseline scan 
except a slight decrease at 7 days (P = 0.0469). 
The mean ADC in treated tumors 1 day after 
IRE was significantly higher than at baseline (P 
= 0.0156) and also compared with the untreat-
ed tumor at 1 day (P = 0.0012) (Figure 2B).
Histopathology 
Representative histology sections correspond-
ing to the untreated and treated lesions in the 
same mouse are shown in Figure 3. The first 
and second rows are untreated and IRE-treated 
Figure 2. Volume variation and ADC variation after IRE. Relative volume change in treated (red) and untreated (blue) 
tumors at baseline (0 days), 1, 3 and 7 days after IRE; the error bars represent the standard deviation across the 7 
studied mice, showing a high variability in both groups (A). Mean ADC in treated (red) and untreated (blue) tumors 
at baseline (0 days), 1, 3 and 7 days after IRE; the error bars represent the standard deviation across the 7 studied 
mice, showing a high variability especially in treated lesions at 1 day (B).
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tumors respectively, whereas each column cor-
responds to a different staining (Caspase-3 1 
and 14 days after IRE, H&E, F4/80 and CD3). 
Image magnification is 40 × for all panels. 
At 1 day post-IRE, extensive activation of cas-
pase-3 was shown in treated tumors compared 
to untreated tumors in the same mice. At 14 
days post-IRE, the caspase-3 activation was no 
longer visible over a necrotic background 
across the entire lesion, but the number of 
apoptotic cells was still significantly higher than 
in untreated tumors. At 14 days we also found 
a significantly lower number of tumor cells (H&E 
Figure 3. Representative histology sections. Sections corresponding to the untreated and treated lesions in the 
same mouse are shown in the first and second row respectively, whereas each column corresponds to a different 
staining (Caspase 3-1 and 14 days after IRE, H&E, F4/80 and CD3). Image magnification is 40 × for all panels. 
Extensive apoptosis is evident at 1 day and no more visible at 14 days in treated tumors; a lower number of tumor 
cells, as well as a higher number of macrophages and T cells, are present at 14 days in treated tumors.
Figure 4. Histology quantitative results. Number of apoptotic cells (caspase-3 staining), tumor cells (H&E staining), 
macrophages (F4/80 staining) and T cells (CD3 staining) found in treated and untreated lesions. The values are 
shown as mean ± SD across the different mice. There was significantly extensive apoptosis between treated and 
untreated tumors at 1 day (P = 0.008) (A) and 14 days (P = 0.008) (B). There was a lower number of tumor cells in 
treated lesions comparing untreated lesions at 14 days post-IRE (P = 0.016) (C), as well as a higher number of mac-
rophages (D) and T cells (E) are present at 14 days in treated tumors comparison with those of untreated tumors 
(macrophage, treated vs. untreated P = 0.04; T cell, treated vs. untreated P = 0.008).
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staining) and a significantly higher number of T 
cells in treated tumors when compared with 
untreated tumors (CD3 staining), whereas the 
number of macrophages (F4/80 staining) was 
trending to be higher but this difference did not 
achieve statistical significance with current 
sample size (Figure 4).
Correlation between the ADC and histopathol-
ogy measurements
The results of all the correlations between the 
dMRI-derived and histology-derived measures 
are reported in Tables 1 and 2 for treated and 
untreated lesions respectively. The most rele-
vant results will be described below.
In the treated tumors, there was a strong cor-
relation between the ADC relative change 1 day 
after treatment and the number of apoptotic 
cells at the same time point. Also, the mean 
and standard deviation of the ADC at 1 day had 
a correlation, though weaker, with the number 
standard deviation and the number of apoptot-
ic and tumor cells.
In untreated tumors, a positive correlation was 
found between the ADC mean and standard 
deviation at 1 day and the number of apoptotic 
cells at 14 days.
By contrast, the MRI-derived volume change at 
7 days had only a weak negative correlation 
with the ADC relative change at 1 day in treated 
tumors (τ = -0.62) and even weaker correla-
tions with the other dMRI values at 1 day (data 
not shown).
Discussion
We studied the effect of IRE treatment in a 
murine pancreatic cancer model with longitudi-
nal ADC measurements, correlated with histo-
pathology data at both early and late time 
points.
We observed a transient dramatic increase of 
the mean ADC in tumors treated with IRE 1 day 
Table 1. Correlation results in treated tumors
ADC-1 day ADC-7 days
Mean Mean % change SD Mean
Mean % 
change SD
Apoptotic cells-1 day +0.70 +0.90 +0.70 - - -
Apoptotic cells-14 days +0.00 +0.60 -0.80 -1.00 -0.40 -0.60
Tumor cells-14 days +0.40 +0.60 -0.80 -0.60 -0.40 -0.60
T cells-14 days -0.20 -0.80 +0.60 +0.80 +0.20 +0.80
Macrophages-14 days -0.60 0.00 -0.20 -0.40 +0.20 0.00
Kendall’s tau values obtained in treated tumors for the correlations between the 
histology-derived quantitative measures specified in each row and the mean value 
(mean), the relative difference between the mean value and the baseline mean 
value (mean % change), and the standard deviation (SD) of the ADC measured at 1 
day (first 3 columns) or at 7 days (last 3 columns). 
Table 2. Correlation results in untreated tumors
ADC-1 day ADC-7 days
Mean Mean % change SD Mean
Mean % 
change SD
Apoptotic cells-1 day -0.20 +0.30 0.00 - - -
Apoptotic cells-14 days +0.95 +0.11 +0.74 +0.74 +0.74 -0.11
Tumor cells-14 days -0.40 +0.40 -0.20 -0.60 -0.20 -0.40
T cells-14 days +0.20 -0.20 0.00 +0.40 0.00 +0.20
Macrophages-14 days +0.20 -0.20 0.00 +0.40 0.00 +0.20
Kendall’s tau values obtained in untreated tumors for the correlations between the 
histology-derived quantitative measures specified in each row and the mean value 
(mean), the relative difference between the mean value and the baseline mean 
value (mean % change), and the standard deviation (SD) of the ADC measured at 1 
day (first 3 columns) or at 7 days (last 3 columns). 
of apoptotic cells at 1 day. By 
contrast, there was no evident 
correlation in untreated tu- 
mors at this early time point.
In untreated tumors there was 
a moderate positive correla-
tion between the mean ADC 
measured at 7 days and the 
number of apoptotic cells at 
14 days. In treated tumors, 
the mean ADC measured 7 
days after IRE had a strong 
negative correlation with the 
number of apoptotic cells, 
and a positive correlation with 
the number of T-cells found at 
14 days. There was also a 
strong correlation between 
the within-ROI standard devia-
tion of the ADC measure-
ments in the treated tumors 
at 7 days and the number of 
T-cells found at 14 days. 
When the 1-day dMRI and the 
14-day histology data were 
compared in the treated 
lesions, the strongest correla-
tions (all negative) were found 
between the 1-day ADC 
change and the number of 
T-cells and between the ADC 
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after the procedure and a return to pre-treat-
ment values as early as 2 days later. The few 
previous studies applying dMRI after IRE treat-
ment did not examine multiple non-acute times, 
and reported contradictory results, particularly 
in preclinical studies. Rat models showed no 
effect on dMRI [19] or an ADC increase 5 to 25 
minutes after electroporation [21], while mouse 
models showed an ADC increase 30 minutes 
after IRE [20] or an ADC reduction 1 and 3 
hours after treatment followed by progressive 
normalization at 6 and 24 hours [18]. In 
patients, one study found an ADC decrease for 
the first 24 hours after the procedure, followed 
by an increase above the pre-treatment values 
1 to 12 months later [17]; another study found 
no significant differences in ADC 1 to 6 months 
after IRE [13]. The different extent and timing of 
the multiple mechanisms involved in the 
response to IRE treatment could explain the 
observed discrepancies.
We found a very strong correlation between the 
1-day ADC change in treated tumors and the 
number of apoptotic cells measured at 1 day, 
suggesting that this dramatic ADC increase 
may be driven mostly by apoptosis.
At later time points, the ADC in untreated 
tumors correlated positively with apoptosis and 
negatively, though weakly, with the number of 
tumor cells, as expected and shown by many 
studies [27]. On the other hand, the ADC in 
treated tumors showed not only a weak nega-
tive correlation with the number of tumor cells, 
similar to untreated tumors, but also a positive 
correlation with the number of T cells and, sur-
prisingly, a very strong negative correlation with 
apoptosis. Thus, the ADC in treated tumors may 
depend upon different factors than in the 
untreated tumors. Even though the values are 
very similar in the two groups, the tumor micro-
environment is probably quite different and in 
fact the observed ADC normalization was not a 
sign of return to normal conditions. Further 
analysis would be needed to derive more 
detailed and specific conclusions.
The most intriguing results are those associat-
ing the 1-day ADC with long-term histopatholo-
gy data. In treated tumors, the ADC relative 
change 1 day after treatment was positively 
correlated with the number of T cells found 14 
days after treatment, so the ADC increase is 
apparently a biomarker of poor tumor response, 
even though it is associated with the degree of 
apoptosis at 1 day; the weak correlation 
between the 1-day relative ADC change and the 
number of tumor cells somewhat supports this 
unexpected result, but further studies are 
needed for confirmation.
The ADC standard deviation within the treated 
tumors had a strong negative correlation with 
the number of tumor cells and a weaker posi-
tive correlation with the number of T cells at 14 
days. It had also a negative correlation with the 
number of apoptotic cells, but apoptosis occurs 
primarily in the acute post-treatment stage and 
is not a mechanism of primary importance in 
the sub-acute phases, as shown by comparing 
our 1-day and 14-days measurements. Thus, 
according to our results, tumors with a less 
homogeneous ADC 1 day after IRE tend to 
respond better to the treatment.
An unexpected result of this study is the strong 
correlation found in untreated tumors between 
the ADC at 1 day (approximately 2 weeks after 
tumor cell injection) and the number of apop-
totic cells at 14 days (approximately 1 month 
after tumor cell injection). This suggests that 
the microstructural information provided by the 
ADC could help predict the natural evolution of 
the tumors. Prior studies have sought to devel-
op mathematical models to predict tumor 
growth based on MRI, but most of these have 
only estimated the future tumor volume [28-
30], whereas our results suggest that even 
microstructural and functional features could 
be predicted. Future studies should investigate 
this possibility, applying multiple MRI tech-
niques and correlating quantitative MRI param-
eters at early time points with histopathological 
data at late time points, similarly to the work of 
Ng et al. [31].
The main limitation of this study was the rela-
tively low number of animals used in each 
group, which might have limited the statistical 
significance of the analysis. Moreover, we 
selected relatively few time points and found 
statistically significant differences only 1 day 
after treatment; additional acute MRI acquisi-
tions may have improved insights into tumor 
response to IRE. However, no previous work 
has attained such a thorough longitudinal MRI 
time-course after IRE with both early and late 
histopathology correlations. We believe that 
our study represents a necessary step towards 
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a better understanding of IRE treatment 
effects. Nonetheless, more detailed analyses 
should be performed in the future to confirm 
and refine our results.
In conclusion, we described a transient dramat-
ic ADC increase, strongly correlated with apop-
tosis, one day after IRE treatment in mouse 
pancreatic tumors. At later time points the ADC 
returned to pre-treatment values, while histo-
pathological data showed quite different fea-
tures and a different relation between these 
measurements and the ADC in treated and 
untreated pancreatic tumors. We also showed 
that dMRI could be an early non-invasive meth-
od to predict response to IRE treatment of pan-
creatic cancer, as well as the microstructural 
evolution of untreated tumors.
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